Weight-loss drugs are transforming both health care and Wall Street, with leading manufacturers like Eli Lilly & Co. (LLY) ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will summarize the bulls’ thesis on NVO.

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

Robert F. Kennedy Jr., President Trump's nominee to lead HHS, spoke highly of GLP-1 drugs at a Senate confirmation hearing ...

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in ...

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

A multi-million dollar Super Bowl ad from telehealth company Hims and Hers downplays risks and side effects of compounded ...

Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...